Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer

Shu Xia, Manish Kohli, Meijun Du, Rachel L. Dittmar, Adam Lee, Debashis Nandy, Tiezheng Yuan, Yongchen Guo, Yuan Wang, Michael R. Tschannen, Elizabeth Worthey, Howard Jacob, William See, Deepak Kilari, Xuexia Wang, Raymond L. Hovey, Chiang Ching Huang, Liang Wang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Liquid biopsies, examinations of tumor components in body fluids, have shown promise for predicting clinical outcomes. To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall survival, we applied whole genome and targeted sequencing to examine the plasma cfDNAs derived from 20 patients with advanced prostate cancer. Sequencing-based genomic abnormality analysis revealed locusspecific gains or losses that were common in prostate cancer, such as 8q gains, AR amplifications, PTEN losses and TMPRSS2-ERG fusions. To estimate tumor burden in cfDNA, we developed a Plasma Genomic Abnormality (PGA) score by summing the most significant copy number variations. Cox regression analysis showed that PGA scores were significantly associated with overall survival (p < 0.04). After androgen deprivation therapy or chemotherapy, targeted sequencing showed significant mutational profile changes in genes involved in androgen biosynthesis, AR activation, DNA repair, and chemotherapy resistance. These changes may reflect the dynamic evolution of heterozygous tumor populations in response to these treatments. These results strongly support the feasibility of using non-invasive liquid biopsies as potential tools to study biological mechanisms underlying therapy-specific resistance and to predict disease progression in advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)16411-16421
Number of pages11
JournalOncotarget
Volume6
Issue number18
StatePublished - 2015

Fingerprint

Prostatic Neoplasms
Androgens
Biopsy
Drug Therapy
Neoplasms
Survival
DNA
Body Fluids
Therapeutics
Plasma Cells
Tumor Burden
DNA Repair
Disease Progression
Regression Analysis
Genome
Population
Genes

Keywords

  • Cell free DNA
  • Liquid biopsy
  • Next generation sequencing
  • Plasma
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Xia, S., Kohli, M., Du, M., Dittmar, R. L., Lee, A., Nandy, D., ... Wang, L. (2015). Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget, 6(18), 16411-16421.

Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. / Xia, Shu; Kohli, Manish; Du, Meijun; Dittmar, Rachel L.; Lee, Adam; Nandy, Debashis; Yuan, Tiezheng; Guo, Yongchen; Wang, Yuan; Tschannen, Michael R.; Worthey, Elizabeth; Jacob, Howard; See, William; Kilari, Deepak; Wang, Xuexia; Hovey, Raymond L.; Huang, Chiang Ching; Wang, Liang.

In: Oncotarget, Vol. 6, No. 18, 2015, p. 16411-16421.

Research output: Contribution to journalArticle

Xia, S, Kohli, M, Du, M, Dittmar, RL, Lee, A, Nandy, D, Yuan, T, Guo, Y, Wang, Y, Tschannen, MR, Worthey, E, Jacob, H, See, W, Kilari, D, Wang, X, Hovey, RL, Huang, CC & Wang, L 2015, 'Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer', Oncotarget, vol. 6, no. 18, pp. 16411-16421.
Xia, Shu ; Kohli, Manish ; Du, Meijun ; Dittmar, Rachel L. ; Lee, Adam ; Nandy, Debashis ; Yuan, Tiezheng ; Guo, Yongchen ; Wang, Yuan ; Tschannen, Michael R. ; Worthey, Elizabeth ; Jacob, Howard ; See, William ; Kilari, Deepak ; Wang, Xuexia ; Hovey, Raymond L. ; Huang, Chiang Ching ; Wang, Liang. / Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. In: Oncotarget. 2015 ; Vol. 6, No. 18. pp. 16411-16421.
@article{efd5e205f342491c90a72a6ecc5df04c,
title = "Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer",
abstract = "Liquid biopsies, examinations of tumor components in body fluids, have shown promise for predicting clinical outcomes. To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall survival, we applied whole genome and targeted sequencing to examine the plasma cfDNAs derived from 20 patients with advanced prostate cancer. Sequencing-based genomic abnormality analysis revealed locusspecific gains or losses that were common in prostate cancer, such as 8q gains, AR amplifications, PTEN losses and TMPRSS2-ERG fusions. To estimate tumor burden in cfDNA, we developed a Plasma Genomic Abnormality (PGA) score by summing the most significant copy number variations. Cox regression analysis showed that PGA scores were significantly associated with overall survival (p < 0.04). After androgen deprivation therapy or chemotherapy, targeted sequencing showed significant mutational profile changes in genes involved in androgen biosynthesis, AR activation, DNA repair, and chemotherapy resistance. These changes may reflect the dynamic evolution of heterozygous tumor populations in response to these treatments. These results strongly support the feasibility of using non-invasive liquid biopsies as potential tools to study biological mechanisms underlying therapy-specific resistance and to predict disease progression in advanced prostate cancer.",
keywords = "Cell free DNA, Liquid biopsy, Next generation sequencing, Plasma, Prostate cancer",
author = "Shu Xia and Manish Kohli and Meijun Du and Dittmar, {Rachel L.} and Adam Lee and Debashis Nandy and Tiezheng Yuan and Yongchen Guo and Yuan Wang and Tschannen, {Michael R.} and Elizabeth Worthey and Howard Jacob and William See and Deepak Kilari and Xuexia Wang and Hovey, {Raymond L.} and Huang, {Chiang Ching} and Liang Wang",
year = "2015",
language = "English (US)",
volume = "6",
pages = "16411--16421",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "18",

}

TY - JOUR

T1 - Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer

AU - Xia, Shu

AU - Kohli, Manish

AU - Du, Meijun

AU - Dittmar, Rachel L.

AU - Lee, Adam

AU - Nandy, Debashis

AU - Yuan, Tiezheng

AU - Guo, Yongchen

AU - Wang, Yuan

AU - Tschannen, Michael R.

AU - Worthey, Elizabeth

AU - Jacob, Howard

AU - See, William

AU - Kilari, Deepak

AU - Wang, Xuexia

AU - Hovey, Raymond L.

AU - Huang, Chiang Ching

AU - Wang, Liang

PY - 2015

Y1 - 2015

N2 - Liquid biopsies, examinations of tumor components in body fluids, have shown promise for predicting clinical outcomes. To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall survival, we applied whole genome and targeted sequencing to examine the plasma cfDNAs derived from 20 patients with advanced prostate cancer. Sequencing-based genomic abnormality analysis revealed locusspecific gains or losses that were common in prostate cancer, such as 8q gains, AR amplifications, PTEN losses and TMPRSS2-ERG fusions. To estimate tumor burden in cfDNA, we developed a Plasma Genomic Abnormality (PGA) score by summing the most significant copy number variations. Cox regression analysis showed that PGA scores were significantly associated with overall survival (p < 0.04). After androgen deprivation therapy or chemotherapy, targeted sequencing showed significant mutational profile changes in genes involved in androgen biosynthesis, AR activation, DNA repair, and chemotherapy resistance. These changes may reflect the dynamic evolution of heterozygous tumor populations in response to these treatments. These results strongly support the feasibility of using non-invasive liquid biopsies as potential tools to study biological mechanisms underlying therapy-specific resistance and to predict disease progression in advanced prostate cancer.

AB - Liquid biopsies, examinations of tumor components in body fluids, have shown promise for predicting clinical outcomes. To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall survival, we applied whole genome and targeted sequencing to examine the plasma cfDNAs derived from 20 patients with advanced prostate cancer. Sequencing-based genomic abnormality analysis revealed locusspecific gains or losses that were common in prostate cancer, such as 8q gains, AR amplifications, PTEN losses and TMPRSS2-ERG fusions. To estimate tumor burden in cfDNA, we developed a Plasma Genomic Abnormality (PGA) score by summing the most significant copy number variations. Cox regression analysis showed that PGA scores were significantly associated with overall survival (p < 0.04). After androgen deprivation therapy or chemotherapy, targeted sequencing showed significant mutational profile changes in genes involved in androgen biosynthesis, AR activation, DNA repair, and chemotherapy resistance. These changes may reflect the dynamic evolution of heterozygous tumor populations in response to these treatments. These results strongly support the feasibility of using non-invasive liquid biopsies as potential tools to study biological mechanisms underlying therapy-specific resistance and to predict disease progression in advanced prostate cancer.

KW - Cell free DNA

KW - Liquid biopsy

KW - Next generation sequencing

KW - Plasma

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84937898954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937898954&partnerID=8YFLogxK

M3 - Article

C2 - 25915538

AN - SCOPUS:84937898954

VL - 6

SP - 16411

EP - 16421

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -